Early changes of muscle insulin‐like growth factor‐1 and myostatin gene expression in gastric cancer patients

Cachexia increases morbidity and mortality of cancer patients. The progressive loss of muscle mass negatively affects physical function and quality of life. We previously showed reduced muscle insulin‐like growth factor‐1 (IGF‐1) expression and enhanced myostatin signaling in tumor‐bearing animals. This study was aimed at investigating whether similar perturbations occur in gastric cancer patients.

[1]  P. Magni,et al.  Impaired Expression of Insulin-Like Growth Factor-1 System in Skeletal Muscle of Amyotrophic Lateral Sclerosis Patients , 2012, Muscle & nerve.

[2]  M. Muscaritoli,et al.  Changes in Myostatin Signaling in Non-Weight-Losing Cancer Patients , 2012, Annals of Surgical Oncology.

[3]  Paula Ravasco,et al.  Definition and classification of cancer cachexia: an international consensus. , 2011, The Lancet. Oncology.

[4]  P. Hasselgren,et al.  CALPAIN activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss , 2011, Muscle & nerve.

[5]  P. Hasselgren,et al.  Sepsis downregulates myostatin mRNA levels without altering myostatin protein levels in skeletal muscle , 2010, Journal of cellular biochemistry.

[6]  D. Lacey,et al.  Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival , 2010, Cell.

[7]  Cunming Duan,et al.  Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins: roles in skeletal muscle growth and differentiation. , 2010, General and comparative endocrinology.

[8]  V. Baracos,et al.  MAFbx/Atrogin-1 expression is a poor index of muscle proteolysis. , 2010, Current opinion in clinical nutrition and metabolic care.

[9]  S. Anker,et al.  Consensus on cachexia definitions. , 2010, Journal of the American Medical Directors Association.

[10]  G. Biolo,et al.  Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". , 2010, Clinical nutrition.

[11]  T. Zimmers,et al.  Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. , 2010, Biochemical and biophysical research communications.

[12]  P. Costelli,et al.  Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice. , 2009, Current cancer drug targets.

[13]  A. Russell,et al.  Atrogin‐1, MuRF1, and FoXO, as well as phosphorylated GSK‐3β and 4E‐BP1 are reduced in skeletal muscle of chronic spinal cord–injured patients , 2009, Muscle & nerve.

[14]  K. Tsuchida.  Targeting myostatin for therapies against muscle-wasting disorders. , 2008, Current opinion in drug discovery & development.

[15]  M. Muscaritoli,et al.  Muscle myostatin signalling is enhanced in experimental cancer cachexia , 2008, European journal of clinical investigation.

[16]  F. Walsh,et al.  Myostatin as a therapeutic target for musculoskeletal disease , 2008, Cellular and Molecular Life Sciences.

[17]  P. Costelli,et al.  Muscle wasting in diabetic and in tumor-bearing rats: role of oxidative stress. , 2008, Free radical biology & medicine.

[18]  K. Tsuchida,et al.  Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. , 2008, Endocrine journal.

[19]  P. Tien,et al.  Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice , 2007, Cancer Gene Therapy.

[20]  M. Muscaritoli,et al.  IGF-1 is downregulated in experimental cancer cachexia. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.

[21]  C. Dejong,et al.  Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. , 2005, The international journal of biochemistry & cell biology.

[22]  P. Hasselgren,et al.  Protein breakdown in muscle from burned rats is blocked by insulin-like growth factor i and glycogen synthase kinase-3beta inhibitors. , 2005, Endocrinology.

[23]  J. Ketelslegers,et al.  Role of the insulin-like growth factor I decline in the induction of atrogin-1/MAFbx during fasting and diabetes. , 2004, Endocrinology.

[24]  T. Braun,et al.  Myostatin mutation associated with gross muscle hypertrophy in a child. , 2004, The New England journal of medicine.

[25]  T. Fielder,et al.  Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin. , 2003, American journal of physiology. Endocrinology and metabolism.

[26]  M. Muscaritoli,et al.  Increased Muscle Proteasome Activity Correlates With Disease Severity in Gastric Cancer Patients , 2003, Annals of surgery.

[27]  V. Paralkar,et al.  Myostatin expression in age and denervation-induced skeletal muscle atrophy. , 2003, Journal of musculoskeletal & neuronal interactions.

[28]  Se-Jin Lee,et al.  Regulation of myostatin activity and muscle growth , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Oldham,et al.  Myostatin regulation during skeletal muscle regeneration , 2000, Journal of cellular physiology.

[30]  D. Halliday,et al.  Changes in protein turnover, IGF‐I and IGF binding proteins in children with cancer , 1998, Acta paediatrica.

[31]  Se-Jin Lee,et al.  Double muscling in cattle due to mutations in the myostatin gene. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Sklar,et al.  Stimulation of Myogenic Differentiation by a Neuregulin, Glial Growth Factor 2 , 1996, The Journal of Biological Chemistry.

[33]  C. Lang,et al.  Differential tissue regulation of insulin-like growth factor-I content and binding proteins after endotoxin. , 1994, Endocrinology.